Heart failure — Research & Evidence

Q: What does the research say about Heart failure?

The scientific consensus on Heart failure is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims: 0 agreements and 0 contradictions.

Q: What do clinical guidelines recommend for Heart failure?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What does the research say about Heart failure?

Emerging pathwayBased on 100 claims (0 agreements, 0 contradictions)

Emerging evidence with 100 primary claims

Clinical questions in Heart failure

Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.

Does vericiguat vs placebo improve outcomes in Heart Failure, Systolic?

Low Certainty+ Favors benefit

vericiguat vs placebo · Left Ventricular Ejection Fraction

15 studies · 30,898 patients· 47 estimates

Does sacubitril / valsartan vs valsartan improve outcomes in Heart Failure, Diastolic?

Low Certainty+ Favors benefit

sacubitril / valsartan vs valsartan · Left Ventricular Ejection Fraction

14 studies · 19,164 patients· 37 estimates

Does beta-blockers vs angiotensin-converting enzyme inhibitors improve outcomes in Heart Failure, Systolic?

Low Certainty+ Favors benefit

beta-blockers vs angiotensin-converting enzyme inhibitors · Left Ventricular Ejection Fraction

5 studies · 15,537 patients· 17 estimates

Does furosemide vs placebo improve outcomes in Heart failure?

Low Certainty+ Favors benefit

furosemide vs placebo · Cardiac Output

22 studies · 14,072 patients· 45 estimates

Does darbepoetin alfa vs placebo improve outcomes in Chronic heart failure?

Low Certainty+ Favors benefit

darbepoetin alfa vs placebo · Left Ventricular Ejection Fraction

5 studies · 9,265 patients· 9 estimates

Does beta-blockers vs angiotensin-converting enzyme inhibitors improve Myocardial Infarction Hospitalization in Heart failure?

Low Certainty+ Favors benefit

beta-blockers vs angiotensin-converting enzyme inhibitors · Myocardial Infarction Hospitalization

2 studies · 4,028 patients· 2 estimates

Does angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers improve outcomes in Heart failure?

Low Certainty+ Favors benefit

angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers · Myocardial Infarction Hospitalization

3 studies · 1,404 patients· 34 estimates

Does loop diuretic vs placebo improve outcomes in Heart failure?

Low Certainty+ Favors benefit

loop diuretic vs placebo · Cardiac Output

4 studies · 622 patients· 37 estimates

Does valsartan vs placebo improve outcomes in Chronic heart failure?

Low Certainty+ Favors benefit

valsartan vs placebo · Serum Creatinine

5 studies· 7 estimates

Does omecamtiv mecarbil vs placebo improve outcomes in Heart failure?

Low Certainty+ Favors benefit

omecamtiv mecarbil vs placebo · All-Cause Mortality

3 studies· 19 estimates

Does spironolactone vs placebo improve outcomes in Heart Failure, Diastolic?

Low Certainty− Favors harm

spironolactone vs placebo · Left Ventricular Ejection Fraction

34 studies · 9,290,492 patients· 64 estimates

Does diuretics vs placebo improve outcomes in Heart failure?

Low Certainty− Favors harm

diuretics vs placebo · Body Weight Change

43 studies · 468,096 patients· 81 estimates

Browse all 24 questions

Where the evidence is moving in Heart failure

Questions where the synthesized consensus has shifted as new trials were indexed.

Does omecamtiv mecarbil vs placebo improve outcomes in Heart Failure, Systolic?

Low Certainty− Favors harm

omecamtiv mecarbil vs placebo · Left Ventricular Ejection Fraction

6 studies · 25,158 patients· 13 estimates· ↑ Strengthening

Evidence brief: Heart failure

Heart failure (also known as HF, CHF, congestive heart failure). General heart failure research and clinical updates

Synapse tracks 24 specific clinical questions in Heart failure, each synthesized independently from its own trial evidence. They include: "Does vericiguat vs placebo improve outcomes in Heart Failure, Systolic?"; "Does sacubitril / valsartan vs valsartan improve outcomes in Heart Failure, Diastolic?"; "Does beta-blockers vs angiotensin-converting enzyme inhibitors improve outcomes in Heart Failure, Systolic?"; "Does furosemide vs placebo improve outcomes in Heart failure?"; "Does darbepoetin alfa vs placebo improve outcomes in Chronic heart failure?".

As of 2026-06-25, the scientific consensus on Heart failure is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on Heart failure. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/69b0a304b42209bc31dca330.

Deterministic synthesis from Synapse's enriched corpus — 276 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for Heart failure?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

Follow the latest Heart failure research

Explore every Heart failure paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.

Search Heart failure papers